Occlusion dysfunction (OD) is causally linked to an increased risk of Alzheimer’s disease (AD), while dentures restoration can mitigate this risk. Highlights: Periodontal disease (PD) and Alzheimer’s do not have a direct causal relationship (P = 0.395). Loose teeth significantly increase the risk of AD progression (P = 0.017, OR = 187.3567). Dentures restoration is …
A study found shared brain-specific mechanisms between Alzheimer’s disease (AD) and depression, particularly involving synaptic signaling and immune system pathways in the hippocampus, but no direct genetic overlap. Highlights: Six brain-specific eQTL genes (SRA1, MICA, PCDHA7, PCDHA8, PCDHA10, PCDHA13) are shared between AD and depression. Pathway analysis identified shared biological pathways, including synaptic signaling, myelination, …
The study demonstrated that selegiline (SEL) improves memory performance, reduces anxiety, and modulates oxidative stress in an Alzheimer’s disease (AD) rat model. Highlights: Memory Improvements: SEL administration improved recognition memory, spatial memory, and passive avoidance memory in AD rats. Anxiety Reduction: SEL significantly reduced anxiety-like behavior in AD rats, as evidenced by performance in the …
Lecanemab shows promise in treating Alzheimer’s disease by reducing clinical deterioration and amyloid-beta plaques, but it has significant adverse effects and requires further research for confirmation. Highlights: FDA Approval: The US FDA authorized lecanemab for Alzheimer’s disease treatment in January 2023. Efficacy: Lecanemab significantly reduces clinical deterioration and amyloid-beta plaques in the brain. Adverse Effects: …
TLDR: GLP-1 agonists were found to significantly reduce the risk of dementia in older individuals with type 2 diabetes mellitus (T2DM) compared to DPP-4 inhibitors and sulfonylureas. Highlights: A sequential trial emulation was conducted using data from Swedish national registers from 2010 to 2020, involving 88,381 participants aged 65 or older with T2DM. The incidence …
TLDR: Researchers demonstrated that intranasal administration of the peptide FITC-PHDP5-CPP reverses early cognitive impairment in Alzheimer’s disease (AD) model mice, showing potential as a treatment for AD-associated cognitive decline. Highlights: PHDP5, derived from the pleckstrin homology domain of dynamin 1, inhibits the interaction between dynamin and microtubules, rescuing synaptic dysfunction caused by tau accumulation. The …
TLDR: This study provides evidence that high salt intake is causally associated with an increased risk of developing dementia, including Alzheimer’s disease (AD) and undefined dementia. Highlights: Causal Association: High salt intake is significantly associated with an increased risk of any dementia (OR = 1.73) and specifically Alzheimer’s disease (OR = 2.10). Cognitive Performance: Higher …
Alzheimer’s disease continues to destroy minds, but new gene editing techniques like CRISPR offer hope for better understanding and treating this devastating illness. Key Facts: Alzheimer’s disease is a complex, poorly understood neurodegenerative disorder affecting over 50 million people worldwide. Gene mutations play a role in early-onset Alzheimer’s, but late-onset Alzheimer’s involves a more complex …
Alzheimer’s disease (AD) is a growing global health concern, but current drug therapies have shown limited effectiveness for symptom management and disease modification. Medium chain triglycerides (MCTs) have emerged as a potential nutritional therapy, but evidence remains inconclusive. Key Facts: MCTs may provide an alternative brain fuel source and reduce AD biomarkers like amyloid-beta. Small …
A new drug recently approved for Alzheimer’s disease aims to treat the underlying cause of the condition by removing amyloid plaques in the brain. Though promising, the drug called aducanumab also comes with potential side effects that require careful monitoring. Key facts: Aducanumab is the first drug that targets and removes amyloid plaques, sticky buildups …
